ClinicalTrials.gg
RecruitingNCT07480525Updated Aug 20, 2026

Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

An interventional study of Escitalopram (Oral antidepressant) in Depression - Major Depressive Disorder, sponsored by Peking University. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Peking University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies testing escitalopram in Depression — 6 open to participants now, 7 under way, none of them phase 3. Escitalopram · Depression.

Planned enrollment
36th of 108
200 · median 107
Started
2026
the only one that year
No phase
17 of 108
2 open now
Registered
108th of 108
by date

Among the 108 studies testing escitalopram in Depression, this one is the 36th largest by planned enrollment, is the only one that started in 2026, is one of 17 with no phase, and was the 108th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

6 of the 108 studies testing escitalopram in Depression are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing escitalopram in Depression, or all of them as a file.
02

Study summary

The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression.

This multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.

03

Conditions studied

  • Depression - Major Depressive Disorder

Browse trials for

Keywords

  • depression
  • antidepressant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity.
  2. Meets the diagnostic criteria for depressive disorders according to the , Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI).
  3. Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4.
  4. First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months.
  5. Written obtained from the patient.

Exclusion criteria

Exclusion Criteria:

  1. Meet diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc..
  2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness;
  3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury;
  4. Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5.
  5. Are pregnant or breastfeeding, cannot use reliable during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation.
  6. Have known allergies to escitalopram oxalate or its .
  7. Are currently taking medications that may interfere with the evaluation of escitalopram efficacy.
  8. Have participated in another drug clinical trial within the past 3 months.
  9. Have to MRI scanning, such as metal implants or claustrophobia.
  10. Considered unsuitable for study participation by the investigators for any other reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Escitalopram

    Participants will receive escitalopram oral solution as open-label monotherapy.

    Drug: Escitalopram (Oral antidepressant)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hamilton Depression Rating Scale (HAMD)

    The outcome is assessed by 17-item Hamilton Depression Rating Scale (HAMD-17) Scale. Total HAMD scores range from 0 to 24, with higher scores indicating more severe depressive symptoms. The change of HAMD from baseline to 8-week (after intervention) was used as the primary outcome.

    Time frame: Week 4 and 8 of treatment duration

Secondary outcomes

  1. Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)

    Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS consists of 10 clinician-rated items with a total score ranging from 0 to 60. Higher scores indicate more severe depressive symptoms.

    Time frame: Week 4 and 8 of treatment duration

  2. Response to treatment

    Treatment response is defined as a ≥50% reduction from baseline in either the 17-item Hamilton Depression Rating Scale (HAMD-17) total score or the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.

    Time frame: Week 4 and 8 of treatment duration

  3. Clinical Global Impression-Severity of Illness (CGI-S)

    The Clinical Global Impression-Severity of Illness (CGI-S) scale is a clinician-rated measure of illness severity ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate greater illness severity.

    Time frame: Baseline; Week 4 and 8 of treatment duration

  4. Change from baseline in C-BCT score

    Change from baseline in the Cognitive Bias Questionnaire (C-BCT) T-score. The C-BCT score is standardized as a T-score ranging from 0 to 100. Higher T-scores indicate greater cognitive function.

    Time frame: Week 4 and 8 of treatment duration

  5. Change from baseline in Hamilton Anxiety Rating Scale (HAMA)

    Change from baseline in the Hamilton Anxiety Rating Scale (HAMA) total score. The HAMA contains 14 items with a total score ranging from 0 to 56. Higher scores indicate more severe anxiety symptoms.

    Time frame: Week 4 and 8 of treatment duration

  6. Treatment Emergent Symptom Scale (TESS)

    The Treatment Emergent Symptom Scale (TESS) is used to assess adverse events during treatment. The total score ranges from 0 to 350 (please specify according to the version used). Higher scores indicate greater severity of treatment-emergent adverse effects.

    Time frame: Baseline; Week 4 and 8 of treatment duration

  7. Escitalopram Therapeutic drug monitoring

    Time frame: Week 4 of treatment duration

  8. Change from baseline in Snaith-Hamilton Pleasure Scale (SHAPS)

    Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score. The SHAPS consists of 14 items with a total score ranging from 0 to 56. Higher scores indicate greater anhedonia.

    Time frame: Week 4 and 8 of treatment duration

  9. The Temporal Experience of Pleasure Scale (TEPS)

    Change from baseline in the Temporal Experience of Pleasure Scale (TEPS) total score. The score ranges from 0 to 100 depending on the version used. Higher scores indicate greater hedonic capacity.

    Time frame: Week 4 and 8 of treatment duration

  10. Childhood Trauma Questionnaire (CTQ)

    The Childhood Trauma Questionnaire (CTQ) assesses childhood maltreatment experiences. The total score ranges from 28 to 140. Higher scores indicate more severe childhood trauma.

    Time frame: Baseline

  11. Change from baseline in Ruminative Responses Scale (RRS)

    Change from baseline in the Ruminative Responses Scale (RRS) total score. The total score ranges from 22 to 88. Higher scores indicate greater rumination.

    Time frame: Week 4 and 8 of treatment duration

  12. Change from baseline in Pittsburgh Sleep Quality Index (PSQI)

    Change from baseline in the Pittsburgh Sleep Quality Index (PSQI) global score. The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality.

    Time frame: Week 4 and 8 of treatment duration

  13. Change from baseline in Connor-Davidson Resilience Scale (CD-RISC)

    Change from baseline in the Connor-Davidson Resilience Scale (CD-RISC) total score. The total score ranges from 0 to 100 (25-item version). Higher scores indicate greater psychological resilience.

    Time frame: Week 4 and 8 of treatment duration

  14. Brain imaging features

    Acquisition was performed by magnetic resonance imaging

    Time frame: Week 0 and 8 of treatment duration

  15. Change from baseline in liver function biomarkers

    Change from baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Both biomarkers are measured in IU/L.

    Time frame: Baseline, Week 4, and Week 8 of treatment duration

  16. Change from baseline in lipid biomarkers

    Change from baseline in total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). All biomarkers are measured in mmol/L.

    Time frame: Baseline, Week 4, and Week 8 of treatment duration

  17. Change from baseline in fasting blood glucose

    Change from baseline in fasting blood glucose, measured in mmol/L.

    Time frame: Baseline, Week 4, and Week 8 of treatment duration

  18. Change from baseline in glycated hemoglobin (HbA1c)

    Change from baseline in glycated hemoglobin (HbA1c), measured as percentage (%).

    Time frame: Baseline, Week 4, and Week 8 of treatment duration

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 9 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Mar 18, 2026
StartActual
Mar 20, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07480525
Lead sponsor
Peking University
Collaborators
The First Hospital of Hebei Medical University, First Hospital of China Medical University, Shandong Mental Health Center, Hebei Provincial Mental Health Center
Responsible party
Weihua Yue (Professor, Peking University) — Principal investigator
First posted
Mar 18, 2026
Start date
Mar 20, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 20, 2026

Study contacts

Weihua Yue
Contact
dryue@bjmu.edu.cn
86-010-82805307
Tong Yu
Contact
tongyu@bjmu.edu.cn
86-010-82805307

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Escitalopram

Start the discussion